Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-132222 · Präparat HOS-097208
11 Medicinal product by Effects on medicinal Recommendation concerning co-administration therapeutic areas product levels. with Harvoni Mean ratio (90% confidence interval) for AUC, Cmax, Cmina, b Rifapentine Interaction not studied. Co-administration of Harvoni with rifapentine is Expected: expected to decrease the concentration of ledipasvir ↓ Ledipasvir and sofosbuvir, leading to reduced therapeutic effect ↓ Sofosbuvir of Harvoni. Such co-administration is not ↔ GS-331007 recommended. (Induction of P-gp) SEDATIVES/HYPNOTICS Midazolam (2.5 mg single Observed: No dose adjustment of Harvoni or midazolam is dose)/ ledipasvir (90 mg Midazolam required. single dose) ↔ Cmax 1.07 (1.00, 1.14) ↔ AUC 0.99 (0.95, 1.04) (Inhibition of CYP3A)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifapentine (HOS-116386) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 9b5e4be36a78e390998f4d139dc539b2e38b7cbe1cb34cf5e0123da04cf8a54f · Zeichen 12736–13959 im Abschnitt